Cover Image
市場調查報告書

全球自動及即時微生物的檢驗市場

Automated And Rapid Microbiological Tests

出版商 Global Industry Analysts, Inc. 商品編碼 225190
出版日期 內容資訊 英文 371 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球自動及即時微生物的檢驗市場 Automated And Rapid Microbiological Tests
出版日期: 2014年05月01日 內容資訊: 英文 371 Pages
簡介

本報告提供全球自動及即時微生物的檢驗市場相關調查,提供各產品,各地區的趨勢,今後的年度預測,及加入此市場的主要企業簡介等。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 全球體外診斷市場
    • 自動及即時微生物檢驗引起了微生物學檢驗的革命
    • 與微生物的奮鬥推動市場的成長
    • 自動微生物學的檢驗
    • 病原菌的即時檢測
    • 傳統的快速微生物檢測
    • 新興市場是莫大的成長機會
    • 臨床的應用
    • 非臨床的應用
    • 值得一提的趨勢
    • 生物科技的發展
    • 重點照護快速微生物檢測
  • 競爭
  • 推動市場的要素與趨勢
    • 感染疾病的發病率上升:機會的指標
    • 全球高齡人口的醫療需求高漲
    • HIV蔓延
    • 各地區HIV統計 其他
  • 快速微生物檢測市場面臨的相關課題
    • 驗證
    • 法律規章認證的取得
    • 不符合實驗要求事項
    • 技術課題與成本問題造成食品領域引進快速微生物檢測的障礙
  • 產品/技術概要
  • 自動·快速微生物檢測的應用領域
    • 臨床應用
    • 自動鑑定及敏銳度系統
    • 自動血液培養系統
    • 自動結核系統 其他
  • 產品技術創新/引進
  • 近幾年的產業活動
  • 全球參與企業
    • Abbott Laboratories
    • Abbott Diagnostics
    • Alere Inc.
    • Becton Dickinson and Company
    • bioMerieux SA
    • bioMerieux, Inc.
    • Bio-Rad Laboratories, Inc
    • Cellabs Pty Ltd
    • Celsis International Plc.
    • Coris BioConcept
    • F. Hoffmann-La Roche Ltd.
    • Hologic Gen-Probe Incorporated
    • MedMira, Inc.
    • Meridian Biosciences, Inc.
    • Orasure Technologies, Inc.
    • Orion Diagnostica Oy
    • Quidel Corp.
    • Sekisui Diagnostics
    • Siemens Healthcare Diagnostics, Inc.
    • Thermo Fisher Scientific, Inc.
    • Oxoid Limited
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 其他
  • 南美
    • 巴西
    • 其他
  • 其他各國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1093

This report analyzes the worldwide markets for Automated And Rapid Microbiological Tests in US$ Thousands by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 103 companies including many key and niche players such as -

Abbott Laboratories
Alere Inc.
Becton Dickinson and Company
bioMerieux SA
Bio-Rad Laboratories, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Clinical Applications
      • Automated Identification and Susceptibility Systems
      • Automated Blood Culture Systems
      • Automated Tuberculosis Systems
      • Streptococcal Infection Rapid Tests
      • GC/Chlamydia Rapid Tests
      • Other Automated & Rapid Microbiological Tests
    • Non-Clinical Applications

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Global Invitro-Diagnostics Market
    • Table 1: Global In Vitro Diagnostics (IVD) Market by Geographic Region (2013): Percentage Share Breakdown of Revenues for the United States, Europe, and Rest of World (includes corresponding Graph/Chart)
    • Table 2: Global In-Vitro Diagnostics Market by Sector (2013): Percentage Breakdown of Revenues for Hospital & Commercial Laboratories, Decentralized & Patient Self-Testing, (includes corresponding Graph/Chart)
    • Table 3: Global In-Vitro Diagnostics Market by Segment (2013): Percentage Breakdown of Value Sales for Hematology, Hemostasis, Immunochemistry, Microbiology, Molecular Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood Glucose, and Tissue Diagnostics (includes corresponding Graph/Chart)
    • Table 4: Global In Vitro Diagnostics Market by Leading Player (2013): Percentage Share Breakdown of Revenues for Abbott, Biomerieux, Danaher, J&J, Roche, Siemens and Others (includes corresponding Graph/Chart)
  • Automated and Rapid Microbiological Tests Revolutionize Microbiological Testing
  • Evolutionary Battle against Microbes Drives Market Future
  • Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market
  • Instant Detection of Pathogens - A New Epoch in the Fight for Survival
  • Traditional Rapid Microbiological Tests Make Way for New, Probe Tests
  • Emerging Markets Provide Tremendous Growth Opportunities
  • Clinical Applications
    • Table 5: Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Region: (2014) (includes corresponding Graph/Chart)
    • Table 6: Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Segment: (2014) (includes corresponding Graph/Chart)
  • Non-Clinical Applications
    • Table 7: Global Automated and Rapid Microbiological Tests Market in Non-Clinical Applications by Region: (2014) (includes corresponding Graph/Chart)
  • A Holistic Peek into a Few Noteworthy Trends
  • The Evolution of Biotechnology - A Crucial Step Ahead in the Growing Popularity of Rapid Microbial Tests
  • Point-of-Care Rapid Microbiological Testing: Yet to Realize Its Full Potential...

2. COMPETITION

    • Table 8: Global Microorganism Identification and Resistance Tests Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Becton Dickinson and Co, BioMerieux, and Others (includes corresponding Graph/Chart)
    • Table 9: Global Blood Screening Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Hologic Gen-Probe, Roche and Others (includes corresponding Graph/Chart)
    • Table 10: Global GC-CT Testing Market by Leading Player (2013): Percentage Market Share Breakdown of Value Sales for Becton Dickinson & Co, Hologic Gen- Probe, Qiagen NV, Roche and Others (includes corresponding Graph/Chart)
  • Competitive Dynamics in the C. Difficile Testing Market
    • Table 11: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2013): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian and Others (includes corresponding Graph/Chart)
    • Table 12: Global Immunoassays Market for Clostridium difficile by Leading Player (2013): Percentage Breakdown of Revenues for Meridian and Others (includes corresponding Graph/Chart)
  • A List of Select Molecular C. difficile Test Products

3. MARKET DRIVERS AND TRENDS

  • Increasing Incidence of Infectious Diseases - An Opportunity Indicator
    • Table 13: Reported Cases of Major Infections by Select Geographic Region: 2011
  • Rising Healthcare Needs of Aging Global Population - A Growth Driver
    • Table 14: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 15: Elderly Population (65+ Years) as a % of Total Population (2025) (includes corresponding Graph/Chart)
  • Rising HIV Prevalance - A Key Opportunity Indicator
  • Some Significant HIV Statistics by Region: 2011
    • Table 16: Global Prevalence of HIV Infection in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
    • Table 17: Newly Infected HIV Population in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
    • Table 18: Global HIV Related Deaths in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
    • Table 19: Top Twelve Countries in Apac with The Highest Hiv Incidence (2012) (includes corresponding Graph/Chart)
    • Table 20: Global HIV Prevalence among Adults and Youth in 2010 (includes corresponding Graph/Chart)
  • Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
  • Ultra-Rapid HIV-Screening Tests put up a Strong Fight against HIV-Epidemic
  • Accuracy/Reliability of Home HIV Testing: A Bone of Contention
  • Increase in Healthcare Spending in Emerging Markets to Propel Demand
    • Table 21: Healthcare Spending as % of GDP in Select Countries (2011) (includes corresponding Graph/Chart)
  • Rising Emphasis on Lab Automation to Augur Well for Market Growth
  • Greater Patient Awareness to Drive Growth
  • Advancements in Molecular Diagnostics - A Boon
  • Antibiotic Resistant Bacteria Throws the Spotlight on Microbial Testing
  • Influenza - Boosting Rapid Test Prospects
  • Select FDA-approved Rapid Detection Tests for Flu A&B: (2012)
  • Automated Blood Culture Systems: The Gold Standard in the Fight against Bacteremia
  • Impact of Food Scares on Rapid Microbiological Tests Market
  • Stringent Norms Necessitate Microbial Food Safety Testing
  • Rapid Screening Gains Preference over Traditional Food Testing Procedures
  • Leading Food Processors Resort to Rapid Microbiological Testing
  • Food Packages of the Future Ingrained with Microbial Alert Systems
  • Poultry Industry Embraces Rapid Microbiological Testing Technologies
  • Rapid Microbiological Tests Gain Significance in the Pharma Industry
  • Key Advantages of Rapid Microbiological Tests for Pharma- In a Nutshell
  • Growth Direct(tm) System Creates Waves in the Pharmaceutical Quality Control

4. KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET

  • Validation: An Imperative Prerequisite
  • Obtaining Regulatory Approval: A Major Non-Technical Hindrance
  • Non-Conformance to Testing Requirements: A Weighty Concern
  • Technical and Cost Issues Impede the Uptake of Rapid Microbiological Tests in the Food Sector

5. PRODUCT/TECHNOLOGY OVERVIEW

  • Automated & Rapid Microbiological Tests: A Definition
  • How Does a Rapid Test Work?
  • Enabling Technologies of Automated & Rapid Microbiological Tests
  • Growth-based Technologies
  • Viability-based Technologies
  • Cellular-Component or Artifact-based Technologies
  • Genomics/Proteomics
  • Microarrays/Microfluidics
  • DNA Microchips/Probes
  • Polymerase Chain Reaction (PCR)
  • Immunoassay
  • Nucleic Acid Testing (NAT)
    • Nucleic Acid Probes
    • Signal-Amplified Tests
    • Nucleic Acid Amplification Tests
  • Traditional Methods with Computer-Aided Imaging
  • Combination Methods

6. APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL TESTS - A REVIEW

  • Clinical Applications
  • Automated Identification and Susceptibility Systems
  • Automated Blood Culture Systems
  • Automated Tuberculosis Systems
  • Streptococcus Infection Rapid Tests
    • Streptococcus A Rapid Tests
    • Streptococcus B Rapid Tests
  • GC/Chlamydia Rapid Tests
  • Other Automated & Rapid Microbiological Tests
  • Respiratory Rapid Tests
    • RSV/ Influenza Rapid Tests
  • Gastrointestinal Rapid Tests
    • Giardia Lamblia Rapid Tests
    • H. Pylori Rapid Tests
    • Cryptosporidium Rapid Tests
    • C. Difficile Rapid Tests
  • STD Rapid Tests
    • HIV Rapid Tests
    • Advantages of Rapid HIV Testing
    • Disadvantages of Rapid HIV Testing
  • Syphilis Rapid Tests
  • Applications in Non-Clinical Investigations
  • Food/Water Safety Tests
  • Food Safety Testing: A Lucrative Application Area
    • qPCR Application in Food Microbiology: Study of Select Micro-Organisms by Target Gene and Food Substrate
  • Rapid Microbiological Methods in Pharmaceutical Sector
    • Limitations
    • Advantages
    • Applications in Pharmaceutical Sector
  • Environmental Tests
  • Other Miscellaneous Applications

7. PRODUCT INNOVATIONS/INTRODUCTIONS

  • Neogen Rolls Out NeoFilmTM for Microbial Tests
  • bioMerieux Unveils TEMPO(r) AC Automated Test
  • Neogen Introduces New Soleris(r) Rapid Assays for Sterility Testing
  • Pall Introduces GeneDisc
  • Rapid Micro Biosystems to Launch Next-Generation Growth DirectTM Systems
  • Bruker Unveils Single-Use MALDI BiotargetTM Sample Plates
  • Becton, Dickinson and Company Introduces BD BACTEC(tm) SafePod
  • Applied Visual Sciences Introduces TBDxV(tm) TB Diagnostic Aid
  • Neogen Introduces Faster Soleris(r) Test for Detecting Mold and Yeast
  • BioControl Systems Develops PCR for Detecting Non-O157 Serotypes of STEC
  • InDevR Introduces New Virus Counter
  • MicroPhage Receives Approval from FDA for KeyPath(tm) MRSA/MSSA Blood Culture Test - BT
  • Health Canada Approves DuPont's BAX(r) System Real-Time Assay
  • Neogen Receives Approval from AOAC for Reveal 2.0 Test
  • Life Technologies and University of Pennsylvania School of Veterinary Medicine Introduce TaqMan(r) Salmonella enteritidis Detection Kit
  • AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic Light(tm) PNA FISH(r)
  • Abbott Laboratories Introduces PLEX-ID(tm) Biothreat Assay
  • bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA
  • BD Launches BD Max(tm) Open System
  • Luxcel Biosciences and Mocon Develop GreenLight(tm)900 Series
  • Bruker Launches pTD(tm) for Homeland Security
  • Hygiena International Launches EnSURE

8. RECENT INDUSTRY ACTIVITY

  • MedMira Secures Approval from COFEPRIS
  • MedMira Secures Marketing Approval for Enriched Version of Reveal(r) Rapid HIV Test (Europe)
  • Corgenix Medical Announces Expansion of Viral Hemorrhagic Fever Rapid Testing Facilities in Sierra Leone
  • MedMira and National Research Council of Canada Ink Collaborative Research Agreement
  • CML HealthCare Installs BD Kiestra Total Laboratory Automation System at Central Laboratory
  • BioMerieux Obtains FDA Clearance for Vitek MS Clinical Microbiology System
  • Cepheid Obtains FDA Clearance for Xpert(r) MTB/RIF Test
  • Rapid Micro Biosystems Receives Funding from Various Capital Ventures to Support Growth DirectTM System
  • Instant BioScan Rolls Out Real-Time Microbial System for Water
  • Becton, Dickinson and Company Takes Over KIESTRA Lab Automation
  • Duzen and Bruker Enter into Exclusive Framework Agreement
  • Bruker Enters into Collaboration with Special Bacteriology Reference Laboratory
  • Terumo Completes Merger with CaridianBCT
  • LabCorp to Develop a Novel Laboratory-based Antibiotic Susceptibility Assay
  • Nanosphere Receives FDA Authorization for Marketing BC-GP Test
  • BD Diagnostics Introduces New Molecular Test
  • BD Diagnostics Receives Approval for Plastic Blood Culture Bottles
  • Cepheid Develops Xpert CT/NG and Xpert CT Next-Generation Molecular Products
  • BIT Analytical Instruments and DRG Diagnostics Launch New Product for Analyzing Immunoassays Parameters
  • Verigene System Introduces Instrument for Automatic Bacterial Identification in Blood Culture Test
  • Block Scientific Supplies BACTECTM 9000 Range of Blood Culture Systems
  • Valio Signs Agreement with DSM
  • CML HealthCare Inks Agreement with Becton, Dickinson and Company
  • Abbott Secures CE Marking for PLEX-IDTM System and Clinical Assays
  • Abbott Laboratories and Genetics Laboratory to Enter into Collaboration for Development of Molecular Diagnostic Test
  • Bruker Extends Distribution Agreement with Francisco Soria Melguizo
  • Laboratory Viollier and Bruker Extend Existing Agreement
  • Thermo Fisher Scientific Receives FDA Approval for Sensititre OptiRead Automated Fluorometric Plate Reading System
  • Magellan Biosciences Obtains FDA Approval for Sensititre AIM Automated Inoculation Delivery System
  • bioMerieux Receives FDA Approval for NucliSENS EasyQ(r) MRSA
  • BD Diagnostics Obtains FDA Approval for BD ProbeTecTM Assays
  • Signature Mapping Medical Sciences Receives Order from Aurum Institute for Health Research
  • Mindray Medical Takes Over Stake in Hunan Changsha Tiandiren Biotech
  • UL Acquires MDT and MDRS
  • Thermo Fisher Scientific Takes over TREK Diagnostic Systems
  • Eurofins Acquires Lancaster Laboratories
  • Polyplus-Transfection Inks Agreement with ExcellGene for Transfection Reagents
  • Merck Acquires Microbiology Division of Biotest
  • UL Establishes New Water Testing Laboratory in India
  • Neogen Obtains FDA Clearance Reveal for Salmonella Enteritidis (SE) Fast Test
  • Sekisui Chemical Acquires Diagnostic Products Business of Genzyme
  • Dynacare Laboratories Acquires Bruker MALDI Biotyper System
  • Magellan Biosciences Enters into Partnership with miacom Diagnostics
  • Lonza Signs Distribution Agreement with Roche
  • BD Enters into Collaboration with Bruker Daltonics
  • Seegene Enters into Partnership with Molzym
  • bioMerieux Enters into Partnership with Shanghai Institutes for Biological Sciences
  • Becton, Dickinson and Company Acquires Global Rights to Market Micro PRO
  • Rapid Micro Biosystems Enters Into Partnership with Life Technologies

9. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (USA)
  • Abbott Diagnostics (US)
  • Alere Inc. (US)
  • Becton Dickinson and Company (US)
  • bioMerieux SA (France)
  • bioMerieux, Inc. (USA)
  • Bio-Rad Laboratories, Inc (US)
  • Cellabs Pty Ltd (Australia)
  • Celsis International Plc. (UK)
  • Coris BioConcept (Belgium)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Hologic Gen-Probe Incorporated (US)
  • MedMira, Inc. (Canada)
  • Meridian Biosciences, Inc. (US)
  • Orasure Technologies, Inc. (US)
  • Orion Diagnostica Oy (Finland)
  • Quidel Corp. (US)
  • Sekisui Diagnostics (Japan)
  • Siemens Healthcare Diagnostics, Inc. (USA)
  • Thermo Fisher Scientific, Inc. (US)
  • Oxoid Limited (UK)

10. GLOBAL MARKET PERSPECTIVE

    • Table 22: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 23: World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 24: World 15-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 25: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 26: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 27: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 28: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 29: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 30: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Percentage Breakdown of Dollar Sales for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 31: World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 32: World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 33: World 15-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 34: World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 35: World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 36: World 15-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 37: World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 38: World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 39: World 15-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 40: World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 41: World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 42: World 15-Year Perspective for Streptococcal Infection Rapid Testsin Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 43: World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 44: World Historic Review for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 45: World 15-Year Perspective for GC/ Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 46: World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 47: World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 48: World 15-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 49: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 50: World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 51: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
      • Changing Healthcare Industry Dynamics Affect Rapid and Automated Microbiological Tests Market
    • Table 52: Healthcare Spending as a % of GDP (includes corresponding Graph/Chart)
    • Positive Outlook for Rapid and Automated Microbiological Tests Market
      • Rapidly Ageing Demographics Drive Growth
    • Table 53: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Competition
    • Tracking Trends Across Product Segments
      • Automated Identification & Susceptibility Systems
      • Growing Popularity of FDA-Approved Automated Susceptibility Testing Equipment
      • STD Rapid Tests
      • Market Shares of Leading Players
    • Table 54: The US Market for Syphilis Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Alere, Becton Dickinson and Others (includes corresponding Graph/Chart)
      • HIV Rapid Testing Market
      • Gastrointestinal Rapid Tests
    • Table 55: The US Market for Rotavirus Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)
    • Table 56: The US Market for Giardia Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Meridian Biosciences, and Oxoid (includes corresponding Graph/Chart)
      • Respiratory Rapid Tests
      • Competition
      • Market Share Data of Leading Players
    • Table 57: The US Trichomonas Testing Market by Leading Player (2013): Percentage Breakdown of Revenues for Becton Dickinson and Co, and Hologic GenProbe Inc (includes corresponding Graph/Chart)
    • Table 58: The US Market for Influenza Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Quidel, Thermo Fisher Scientific and Others (includes corresponding Graph/Chart)
    • Table 59: The US Market for RSV Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Binax, Thermo Fisher Scientific and Others (includes corresponding Graph/Chart)
    • Table 60: The US Market for Tuberculosis Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson and Hologic Gen-Probe (includes corresponding Graph/Chart)
    • Table 61: The US Market for M. Pneumoniae Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Meridian Biosciences and Oxoid (includes corresponding Graph/Chart)
    • Table 62: The US Market for Mononucleosis Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Alere, Oxoid, Quidel and Others (includes corresponding Graph/Chart)
      • Streptococcus Infection Rapid Tests
    • Table 63: The US Market for Streptococcus A Rapid Tests by Leading Player (2013) - Percentage Breakdown of Value Sales for Becton Dickinson, Quidel, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)
    • Testing Practices of the US Food Industry
    • Table 64: US Food Safety Testing Market by Contaminant (2013): Percentage Breakdown of Value Sales for Pathogens, GMOs, Toxins, Residues and Others (includes corresponding Graph/Chart)
    • Increasing Demand for Microbiology Tests in the Food Sector
    • Table 65: US Microbiological Food Safety Tests by Type (2013): Percentage Share Breakdown in terms of Number of Tests for Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)
    • Tackling the Burden of Food Borne Illnesses
    • Table 66: Food-borne Illnesses, Hospitalizations and Deaths in the US (2012): Percentage Share Breakdown for Known Pathogens and Unspecified Agents (includes corresponding Graph/Chart)
    • Table 67: Leading Pathogens Causing Food- borne Illnesses in the US (2012): Percentage Share Breakdown of Number of Illnesses by Known Pathogens - Norovirus, Salmonella nontyphoidal, Clostridium perfringens, Campylobacter spp., Staphylococcus aureus, and Others (includes corresponding Graph/Chart)
    • Table 68: Leading Food-borne Pathogens Causing Hospitalizations in the US (2012): Percentage Share Breakdown of Number of Hospitalizations by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)
    • Table 69: Leading Food-borne Pathogens Causing Deaths in the US (2012): Percentage Share Breakdown of Number of Deaths by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 70: The US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 71: The US Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 72: The US 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current & Future Analysis
    • Food Safety Testing in Canada
    • Table 73: Canadian Food-Borne Illnesses by Category (2012): Percentage Share Breakdown of Number of Illness Caused through Known Pathogens and Unknown Pathogens (includes corresponding Graph/Chart)
    • Table 74: Canadian Food-Borne Illnesses by Pathogen (2012): Percentage Breakdown of number of Illness Caused by Norovirus, Clostridium perfringers, Campylobacter spp, Salmonella spp., non-typhoidal and Others (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
    • MedMira, Inc. - A Key Player
  • B. Market Analytics
    • Table 75: Canadian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 76: Canadian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 77: Canadian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Demographics Drive Market Growth
    • Table 78: Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)
    • Table 79: Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Sekisui Diagnostics - A Key Player
  • B. Market Analytics
    • Table 80: Japanese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 81: Japanese Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 82: Japanese 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
      • Debt Crisis in Europe Affects Healthcare Industry
      • European Healthcare System: In a State of Transition?
    • Ageing Demography - An Opportunity Indicator
    • Table 83: Population Breakup by Age Group for Select European Countries: 2011 (as a Percentage of Total Population) (includes corresponding Graph/Chart)
    • Clinical Vis-a-vis Non-clinical Applications
    • What Drives the Requirement Patterns of End-Users?
    • Proliferation of Automated, and Rapid Tests in Clinical Applications
    • Non-clinical Applications
    • Table 84: European Microbiological Food Safety Tests (2012): Percentage Share Breakdown of Number of Tests by Segment - Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 85: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 86: European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 87: European 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, & Rest of Europe for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 88: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 89: European Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 90: European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current & Future Analysis
    • Product Launch
    • Strategic Corporate Development
    • bioMerieux SA - A Key Player
  • B. Market Analytics
    • Table 91: French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 92: French Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 93: French 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Food Safety - A Cause of Concern
    • Food Safety Regulations in Germany
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 94: German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 95: German Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 96: German 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 97: Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 98: Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 99: Italian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
    • Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics
    • Non-Clinical Applications to Exhibit Fastest Growth
    • Key Players
  • B. Market Analytics
    • Table 100: The UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 101: The UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 102: The UK 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 103: Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 104: Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 105: Spanish 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 106: Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 107: Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 108: Russian 15-Year Perspective for Automated & Rapid Microbiological Tests by End- Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 109: Rest of European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 110: Rest of European Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 111: Rest of European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
      • Healthcare Spending in Asia-Pacific on the Rise
    • India & China Offer Significant Growth Opportunities
    • Table 112: China and India Leads Global Population (July 2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart)
    • Table 113: Age-wise Breakup of China and India's Population Vis-a-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart)
    • Asia-Pacific - The Next Epicenter for the AIDS Epidemic
  • B. Market Analytics
    • Table 114: Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 115: Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 116: Asia-Pacific 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 117: Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 118: Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 119: Asia-Pacific 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current & Future Analysis
    • Table 120: Leading Players in the Chinese in Vitro Diagnostics Market (2012): Percentage Breakdown of Value Sales for Abbott, Beckman/ Danaher, BioMerieux, DA AN, Hitachi, J&J, Mindray, Roche, Siemens, Symex and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 121: Chinese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 122: Chinese Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 123: Chinese 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • Current & Future Analysis
      • Demand for Automated and Rapid Microbiology Testing Set to Grow in India
      • Growth Drivers
      • Automation - Name of the Game
  • B. Market Analytics
    • Table 124: Indian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 125: Indian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 126: Indian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Cellabs Pty Ltd - A Key Australian Player
  • B. Market Analytics
    • Table 127: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 128: Rest of Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End- Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 129: Rest of Asia-Pacific 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 130: Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - Brazil and Rest of Latin America Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 131: Latin American Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - Brazil and Rest of Latin America Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 132: Latin American 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin America for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 133: Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 134: Latin American Historic Review for Automated & Rapid Microbiological Tests by End- Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 135: Latin American 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6a. BRAZIL

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 136: Brazilian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 137: Brazilian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 138: Brazilian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6b. REST OF LATIN AMERICA

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 139: Rest of Latin America Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 140: Rest of Latin America Historic Review for Automated & Rapid Microbiological Tests by End- Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 141: Rest of Latin America 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 142: Rest of World Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 143: Rest of World Historic Review for Automated & Rapid Microbiological Tests by End- Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 144: Rest of World 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Back to Top